Which companies overlap with IRCCS Azienda Ospedaliero-Universitaria di Bologna's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Sanofi, AstraZeneca, Biocad, Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/irccs-azienda-ospedaliero-universitaria-di-bologna.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

IRCCS Azienda Ospedaliero-Universitaria di Bologna — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IRCCS Azienda Ospedaliero-Universitaria di Bologna pipeline: 5 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Salbutamol + Tiotropium	Salbutamol + Tiotropium	marketed	Combination bronchodilator (short-acting beta-2 agonist + long-acting anticholinergic)	Beta-2 adrenergic receptor (salbutamol); Muscarinic M3 receptor (tiotropium)	Respiratory/Pulmonology
Placebo + Tiotropium	Placebo + Tiotropium	marketed	Long-acting muscarinic antagonist (LAMA)	M3 muscarinic receptor	Respiratory / Pulmonology
Sequential therapy	Sequential therapy	marketed
Metarapone	Metarapone	marketed			Other
Standardized antihypertensive therapy	Standardized antihypertensive therapy	marketed			Cardiovascular
LMWH parnaparin subcutaneously	LMWH parnaparin subcutaneously	phase 3	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect target); Coagulation factors Xa and IIa	Cardiovascular
Atezolizumab & Bevacizumab	Atezolizumab & Bevacizumab	phase 3	PD-L1 inhibitor + VEGF inhibitor combination	PD-L1 and VEGF	Oncology

Therapeutic area mix

Cardiovascular · 2
Oncology · 1
Other · 1
Respiratory / Pulmonology · 1
Respiratory/Pulmonology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 2 shared drug classes
Sanofi · 2 shared drug classes
AstraZeneca · 1 shared drug class
Biocad · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
Chiesi Farmaceutici S.p.A. · 1 shared drug class
Cristália Produtos Químicos Farmacêuticos Ltda. · 1 shared drug class
Bayer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for IRCCS Azienda Ospedaliero-Universitaria di Bologna:

Cite this brief

Drug Landscape (2026). IRCCS Azienda Ospedaliero-Universitaria di Bologna — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/irccs-azienda-ospedaliero-universitaria-di-bologna. Accessed 2026-05-17.